Skip to Content

Join the 'Hepatitis C' group to help and get support from people like you.

Hepatitis C News

Related terms: Hepatitis C, Chronic, Chronic Hepatitis C, Hep C

FDA Approves Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for Hepatitis C

Posted 8 days ago by Drugs.com

July 18, 2017 – The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A. “Direct-acting antiviral drugs prevent the virus from multiplying and often cure HCV. Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Hepatitis C is a viral di ... Read more

Related support groups: Hepatitis C, Hepatitis, Sofosbuvir, Vosevi, Sofosbuvir/velpatasvir/voxilaprevir, Sofosbuvir/velpatasvir

Surf's Up! How to Plan for a Safe Beach Vacation

Posted 25 Jun 2017 by Drugs.com

SATURDAY, June 24, 2017 – Heading to the beach this summer? Make safety part of your vacation planning. Sun protection belongs at the top of your packing list. Must-haves include sunscreen, sunglasses, protective clothing and a hat, the U.S. Food and Drug Administration says. Here are some of the agency's other recommendations: Don't use tanning beds to pre-tan before a beach vacation. The lamps emit harmful ultraviolet rays that can damage your skin. Also, be aware that spray tans and bronzers do not protect against UV rays. Make a list of medications you need to take, and get enough to last the trip. Keep your medicines with you when traveling. Also, carry a detailed list of what medicines you take and have your health care provider's contact information in case you need medical care while you're away. If you wear contact lenses, pack enough for the entire vacation. Don't forget to ... Read more

Related support groups: Eye Conditions, Hepatitis C, HIV Infection, Sunburn, Sunscreen, Prevention of Sunburn, Visual Defect/Disturbance, Deeptan, Coppertone

U.S. Liver Cancer Deaths Have Doubled Since 1980s: Study

Posted 7 Jun 2017 by Drugs.com

WEDNESDAY, June 7, 2017 – Liver cancer is the fastest-growing cause of cancer deaths in the United States, a new study reports. Liver cancer cases have been on the rise since the mid-1970s, a trend expected to continue through at least 2030. Death rates from the disease have doubled since the mid-1980s – the fastest increase of any cancer, according to the American Cancer Society, which conducted the study. About 41,000 new cases of liver cancer and 29,000 deaths from the disease are projected in the United States this year, the cancer society said. Liver cancer is now the fifth-leading cause of cancer death in men and the eighth-leading cause in women. About 1 percent of people will be diagnosed with the disease during their lives. Only 1 in 5 survives five years after diagnosis, said the researchers led by Dr. Farhad Islami. Islami is strategic director of cancer surveillance ... Read more

Related support groups: Hepatitis C, Liver Cirrhosis, Liver and Pancreatic Disease, Hepatitis B Adult Vaccine, Twinrix, Hepatic Tumor, Vaccination and Prophlaxis, Engerix-B, Hepatitis A Adult Vaccine/hepatitis B Adult Vaccine

New Combo Pill Offers Hope to Hepatitis C Patients Who Fail Other Treatment

Posted 1 Jun 2017 by Drugs.com

WEDNESDAY, May 31, 2017 – A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report. The pill – which contains the antiviral drugs sofosbuvir (Sovaldi), velpatasvir and voxilaprevir – was nearly 100 percent effective in curing hepatitis C in patients whose disease returned after treatment with other antiviral drugs, the researchers said. "Currently, we have very good treatments for hepatitis C, and we are able to achieve a cure in over 90 percent of patients. So globally, although only a few patients relapse, it still is a significant number," said lead researcher Dr. Marc Bourliere, from the Hospital Saint Joseph in Marseilles, France. This new pill is being developed as a rescue treatment for patients who have failed other therapy, he said. When it was used as an initial treatment in ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Epclusa, Sofosbuvir, Ledipasvir/sofosbuvir, Sofosbuvir/velpatasvir

New Hepatitis C Infections Hit 15-Year High: CDC

Posted 14 May 2017 by Drugs.com

FRIDAY, May 12, 2017 – Reports of new hepatitis C infections in the United States nearly tripled over five years, reaching a 15-year high, federal government data show. The highest number of new infections were reported among 20- to 29-year-olds. Many stemmed from the growing use of injected drugs linked to the current opioid epidemic, officials said. The number of reported cases rose from 850 in 2010 to 2,436 in 2015, according to the U.S. Centers for Disease Control and Prevention. But nearly half of people who have the liver infection don't know it, so most new cases are never reported. The CDC estimated there were actually about 34,000 new hepatitis C infections nationwide in 2015. "We must reach the hardest-hit communities with a range of prevention and treatment services that can diagnose people with hepatitis C and link them to treatment. This wide range of services can also ... Read more

Related support groups: Hepatitis C, Viral Infection, Liver and Pancreatic Disease

A 2nd Life for Risky Kidney Transplants?

Posted 11 May 2017 by Drugs.com

THURSDAY, May 11, 2017 – Philadelphia doctors say they cleared hepatitis C infections in 10 patients who received kidneys from deceased donors who had the virus. The findings suggest hundreds more of these transplants could take place each year, thus reducing wait time for a lifesaving kidney, the doctors said. "Our pilot data demonstrate the ability to cure the contracted virus following transplantation in this patient population," said the study co-leader, Dr. David Goldberg. "If future studies are successful, this may be a viable option for patients who may otherwise never see a transplant," added Goldberg, an assistant professor of medicine and epidemiology at the University of Pennsylvania School of Medicine. In the United States, more than 97,000 people need a kidney transplant. Many must wait for five or more years, the researchers said in background notes. Kidneys from donors ... Read more

Related support groups: Hepatitis C, Renal Transplant, Organ Transplant, Kidney Transplant

High Rates of Hepatitis C in Pregnancy Mirror Opioid Epidemic: CDC

Posted 11 May 2017 by Drugs.com

THURSDAY, May 11, 2017 – Chalk up another potential consequence of the U.S. opioid epidemic: The prevalence of hepatitis C infections among pregnant women nearly doubled between 2009 and 2014, U.S. health officials report. Hepatitis C – which is caused most often by injection drug use – rose 89 percent nationwide among pregnant women. Increases were most notable in West Virginia and rural counties in Tennessee, areas hard-hit by the heroin and prescription painkiller epidemic, the U.S. Centers for Disease Control and Prevention reported. Nationwide, 35 infants a day were exposed to the contagious liver disease, on average, study authors said. "We have seen a dramatic increase in opioid use in pregnancy and in the number of infants having drug withdrawal," said report author Dr. Stephen Patrick, of Vanderbilt University Medical Center in Nashville. "Taken together, this suggests that ... Read more

Related support groups: Suboxone, Oxycodone, Hydrocodone, Tramadol, Percocet, Methadone, OxyContin, Vicodin, Norco, Fentanyl, Opiate Dependence, Morphine, Codeine, Lortab, Opiate Withdrawal, Opana, Hepatitis C, Subutex, Dilaudid, Opana ER

New Hepatitis C Treatments More Effective, Tolerable: FDA

Posted 11 May 2017 by Drugs.com

THURSDAY, May 11, 2017 – Hepatitis C can be cured in about three months, allowing people with the viral disease to live longer, healthier lives, the U.S. Food and Drug Administration (FDA) says. Drugs used to clear the virus from the body are not only more effective than they once were but also more tolerable for patients, according to Dr. Jeffrey Murray, an internist at the FDA who specializes in infectious diseases. Hepatitis is inflammation of the liver that is caused by different viruses. In the United States, hepatitis C is the most common chronic bloodborne infection. Avoiding risky behaviors, such as sharing drug needles, can help prevent the spread of the disease, but there is no vaccine for hepatitis C. Hepatitis is often a silent disease. Many people are unaware they are infected for years and learn about their infection only after they have developed serious liver disease or ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Epclusa, Zepatier, Sofosbuvir, Ledipasvir/sofosbuvir, Sofosbuvir/velpatasvir

FDA Approves Sovaldi (sofosbuvir) for Chronic Hepatitis C Infection in Pediatric Patients 12 Years and Older

Posted 8 Apr 2017 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 7, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental indications for Sovaldi (sofosbuvir 400 mg) tablets for the treatment of chronic hepatitis C virus (HCV) infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg. Sovaldi was approved for pediatric patients with genotype 2 or 3 chronic HCV infection, in combination with ribavirin. There are an estimated 23,000-46,000 pediatric HCV patients in the United States, most of whom were infected with the virus at birth. Sovaldi has a boxed warning in their respective product labels regarding the risk of hepatitis B virus reactivation in HCV/HBV co-infected patients. See below for important safety information. Sovaldi for Pediatric Patients The ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

FDA Approves Harvoni (ledipasvir and sofosbuvir) for Chronic Hepatitis C Infection in Pediatric Patients 12 Years and Older

Posted 8 Apr 2017 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 7, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved asupplemental indication for Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) tablets for the treatment of chronic hepatitis C virus (HCV) infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg. Harvoni was approved for pediatric patients with genotype 1, 4, 5 or 6 chronic HCV infection. There are an estimated 23,000-46,000 pediatric HCV patients in the United States, most of whom were infected with the virus at birth. Harvoni has a boxed warning in its product label regarding the risk of hepatitis B virus reactivation in HCV/HBV co-infected patients. See below for important safety information. Harvoni for Pediatric Patients The supplemental new drug ... Read more

Related support groups: Hepatitis C, Harvoni, Ledipasvir/sofosbuvir

FDA Approves Two Hepatitis C Drugs - Sovaldi and Harvoni - for Pediatric Patients

Posted 7 Apr 2017 by Drugs.com

April 7, 2017 – The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Direct-acting antiviral drugs reduce the amount of HCV in the body by preventing the virus from multiplying, and in most cases, they cure HCV. “These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Today’s approvals provide pediatric treatment options for six major genotypes, or strains, of HCV. Harvoni is in ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Sofosbuvir, Ledipasvir/sofosbuvir

FDA Approves Hep C Drugs for Kids 12 and Older

Posted 7 Apr 2017 by Drugs.com

FRIDAY, April 7, 2017 – The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C infection in children aged 12 and older. Both Solvaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are already approved for use in adults, the agency said in a news release Friday. The medications are antivirals that prevent the hepatitis C virus (HCV) from reproducing. "In most cases, they cure HCV," the FDA added. "These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," said Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research. Hepatitis C causes liver inflammation that can lead to liver failure. Between 3 and 4 million people in the United States are infected with the virus, the agency said. Children born to infected mothers are at higher risk ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Epclusa, Sofosbuvir, Ledipasvir/sofosbuvir, Sofosbuvir/velpatasvir

Hepatitis Infection May Raise Risk for Parkinson's Disease

Posted 30 Mar 2017 by Drugs.com

THURSDAY, March 30, 2017 – People with the liver infection hepatitis may be at heightened risk of developing Parkinson's disease, a large new study suggests. The study, published online March 29 in Neurology, is the second in the past year to link hepatitis to Parkinson's. Specifically, the new study found that people who'd been infected with hepatitis B or C were 51 percent to 76 percent more likely to develop Parkinson's, compared to people who'd never had hepatitis. The researchers don't know why the connection exists. And the study cannot prove a cause-and-effect link. But the association between Parkinson's disease and hepatitis appears to be "strong," according to Dr. Michael Okun, national medical director of the Parkinson's Foundation. Last year, a study in Taiwan found that people with hepatitis C faced an increased risk of Parkinson's. Now the new findings, based on millions ... Read more

Related support groups: Hepatitis C, Parkinson's Disease, Hepatitis B, Parkinsonian Tremor, Parkinsonism, Exposure to Hepatitis B Virus

Better Efforts Could Help Rid the U.S. of Hepatitis B, C: Report

Posted 28 Mar 2017 by Drugs.com

TUESDAY, March 28, 2017 – Improved prevention, screening and treatment could help eliminate hepatitis B and C as serious public health problems in the United States and save nearly 90,000 lives by 2030, according to a new report. About 1.3 million people in the United States have chronic hepatitis B and about 2.7 million have chronic hepatitis C. These infections cause about 80 percent of liver cancer cases worldwide. Liver cancer incidence in the United States rose 38 percent between 2003 and 2012. Liver cancer deaths increased 56 percent during that time, primarily due to viral hepatitis, according to the report from the National Academies of Sciences, Engineering, and Medicine. "Viral hepatitis is simply not a sufficient priority in the United States," said report committee chair Dr. Brian Strom, chancellor and professor at Rutgers University Biomedical and Health Sciences in ... Read more

Related support groups: Hepatitis C, Hepatitis B, Hepatitis B Adult Vaccine, Twinrix, Hepatitis B Prevention, Exposure to Hepatitis B Virus, Hepatitis B Prophylaxis, Vaccination and Prophlaxis, Engerix-B, Hepatitis A Adult Vaccine/hepatitis B Adult Vaccine

New Hepatitis C Drugs Might Eliminate the Disease

Posted 20 Mar 2017 by Drugs.com

MONDAY, March 20, 2017 – Newer treatments for hepatitis C appear to eliminate the virus in the vast majority of those taking oral antiviral medications, raising the hope that this disease might someday be eradicated in the United States. The oral medications "work really well in most patients that have hepatitis C," said Dr. Oluwaseun Falade-Nwulia, the study's lead author. She's an assistant professor of medicine at Johns Hopkins University School of Medicine in Baltimore. Most people have a 95 percent chance of being cured, meaning the hepatitis C virus is no longer detectable in a person's bloodstream, the finding showed. "The other big message is that these therapies are very safe. The risk of side effects are very low," she said. Plus, many patients can be treated in just 12 weeks, according to the study published online March 20 in the Annals of Internal Medicine. "It's ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Ribavirin, Epclusa, Sofosbuvir, Copegus, Ribasphere, Interferon Alfa-2B/Ribavirin, Ledipasvir/sofosbuvir, Interferon Alfa-2A, Rebetol, Rebetron, RibaPak, Olysio, Roferon-A, Virazole, Sofosbuvir/velpatasvir, RibaTab, Moderiba

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Infectious Hepatitis

Related Drug Support Groups

Harvoni, Sovaldi, ribavirin, Incivek, Pegasys, Epclusa, Zepatier, Victrelis, sofosbuvir, view more... PegIntron, Daklinza, Viekira Pak, Ribasphere, interferon alfa-2b, Copegus, telaprevir, boceprevir, interferon alfa-2a, ledipasvir / sofosbuvir, Rebetol, interferon alfa-2b / ribavirin, Rebetron, Intron A, Olysio, RibaPak, peginterferon alfa-2b, daclatasvir, Roferon-A, Viekira XR, peginterferon alfa-2a, Technivie, simeprevir, ombitasvir / paritaprevir / ritonavir, Moderiba, Vosevi, RibaTab, sofosbuvir / velpatasvir / voxilaprevir, sofosbuvir / velpatasvir, Infergen, elbasvir / grazoprevir, dasabuvir / ombitasvir / paritaprevir / ritonavir, interferon alfacon-1